JAK2 and myeloproliferative neoplasm: Prestipino et al. also showed that PD-1 inhibition treatment of Jak2-mutated MPN mouse models increased survival rates, decreased the Jak2-related allele burden, and favored CD8+ T cell effectiveness by re-establishing metabolism and cell cycle progression.